# EvoPAR-BR01 (NCT06380751)

> Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06380751
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced Breast Cancer
- Interventions: Saruparib (AZD5305); Camizestrant; Abemaciclib; Ribociclib; Palbociclib; Fulvestrant; Letrozole; Anastrozole; Exemestane
- Enrollment: 788
- Primary outcome: Progression-Free Survival (Arm 1 vs arm 2)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 3
- Podcasts: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evopar-br01-nct06380751